Jiangsu Hengrui Pharmaceuticals surged more than 12 per cent in Hong Kong following strong third-quarter results, as positive momentum continues to buoy Chinese biotech stocks. Hengrui, one of China’s largest drug makers, reported a 20.55 per cent rise in third-quarter revenue to 8.95 billion yuan (US$1.34 billion), beating analyst estimates of 8.55 billion yuan amid stronger innovative drug sales. Net profit reached 2.46 billion yuan for the three months ended September 30, jumping 88.92 per...
Read full article